tirzepatide weight loss clinical trial results once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo- controlled, phase 3 Maintaining Weight Loss: The Efficacy

Product labelling and official guidance highlight important safety issues, including gastrointestinal adverse effects and warnings around use in appropriate patient groups

The medication's primary gastrointestinal side effectsparticularly nausea, vomiting, and diarrheacan lead to dehydration if fluid intake is inadequate or losses are not appropriately replaced

Preferential cell death of CD8+ effector memory (CCR7-CD45RA-) T cells by hydrogen peroxide-induced oxidative stress

Many patients begin to see results within a few weeks, with significant changes typically developing over months when combined with diet and lifestyle changes